How are Cell and Gene therapies transforming patients' lives? What is their impact on the current and future curative treatment landscape? How should pharma manufacturing and other relevant stakeholders plan for a higher degree of operating model sophistication required for Cell and Gene therapies?
What is the focus of the Distributor Paper?In this paper, we will focus on the Cell and Gene therapy product flow, outline the hurdles and opportunities created within supply chain distribution flows, describe alternate distribution models expected in the CGT supply chain and explore the required capabilities.
The paper aims to answer questions such as: